57° Rain

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
News
- Local News
- State News
Sports
- Local Sports
- Pro Sports
Lifestyle
- Local Entertainment
Multimedia
Community Choice
Features
Classifieds
- Place Ad
- Legal Notices
Public Notices
Obituaries
E-Edition

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

132.51 -0.54 (-0.41%)

Streaming Delayed Price Updated: 3:21 PM EDT, May 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9

...

74 75 Next >

Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference ↗

Today 7:05 EDT

Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing...

Via MarketBeat

Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions

Today 1:35 EDT

Gilead Sciences began 2026 with revenue and adjusted earnings per share both exceeding Wall Street expectations, reflecting strong commercial execution and d...

Via StockStory

Topics Earnings

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

May 13, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead (GILD) Q1 2026 Earnings Call Transcript ↗

May 08, 2026

Gilead (GILD) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Gilead Sciences Inc (NASDAQ:GILD) Beats Q1 Estimates But Stock Falls on Hefty Acquisition Costs and Revised Loss Guidance ↗

May 07, 2026

Via Chartmill

These S&P500 stocks are moving in today's pre-market session ↗

May 08, 2026

Via Chartmill

GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook

May 08, 2026

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 4.4% year on year to...

Via StockStory

What's going on in today's after hours session: S&P500 movers ↗

May 07, 2026

Via Chartmill

Gilead Sciences’s (NASDAQ:GILD) Q1 CY2026: Beats On Revenue

May 07, 2026

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 4.4% year on year...

Via StockStory

Gilead Sciences Inc (NASDAQ:GILD): A Balanced Dividend Play with Strong Financial Health and Profitability ↗

April 25, 2026

Via Chartmill

Gilead Sciences (NASDAQ:GILD): A Value Screen Candidate with Strong Profitability ↗

April 20, 2026

Via Chartmill

Gilead Tumbles On Mixed Guidance Update Amid Recent M&A Frenzy ↗

May 07, 2026

Gilead Sciences issued a mixed guidance update late Thursday after the biotech company beat first-quarter sales expectations.

Via Investor's Business Daily

Gilead Sciences Announces First Quarter Financial Results

May 07, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Likely To Report Higher Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

May 07, 2026

Gilead Sciences (NASDAQ: GILD) will release Q1 earnings on May 7, with analysts expecting $1.91 EPS and $6.92B revenue. Stock closed at $136.30 on April 29.

Via Benzinga

A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000 ↗

May 06, 2026

Nurix Therapeutics, a biotech innovator in targeted cancer therapies, reported a notable insider sale amid strong one-year stock gains.

Via The Motley Fool

Topics Regulatory Compliance

Earnings To Watch: Gilead Sciences (GILD) Reports Q1 Results Tomorrow

May 05, 2026

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Thursday after market close. Here’s what you need to know. Gilead Sci...

Via StockStory

Topics Artificial Intelligence

Tempus AI (TEM) Q1 2026 Earnings Transcript ↗

May 05, 2026

Tempus AI (TEM) Q1 2026 Earnings Transcript

Via The Motley Fool

Topics Artificial Intelligence

1 S&P 500 Stock to Own for Decades and 2 We Avoid

May 04, 2026

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...

Via StockStory

Topics Stocks

Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences

May 01, 2026

From Gilead Sciences, Inc.

Via Business Wire

2 Nasdaq 100 Stocks with Solid Fundamentals and 1 We Find Risky

May 01, 2026

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win...

Via StockStory

Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?

April 30, 2026

Though Gilead Sciences has underperformed relative to the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Via Barchart.com

Topics ETFs

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗

April 29, 2026

Via Benzinga

Opes Wealth Sells Its Entire FIXD Stake -- Is This $9.3 Million Bond ETF Exit A Signal? ↗

April 29, 2026

This fixed-income ETF offers diversified bond exposure and a flexible strategy focused on income and sector allocation.

Via The Motley Fool

Topics Bonds ETFs Regulatory Compliance

U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

April 29, 2026

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

April 28, 2026

From Gilead Sciences, Inc.

Via Business Wire

3 Healthcare Stocks That Pay You While You Wait for the Growth ↗

April 27, 2026

It may not seem like it at first, but these dividends are safe.

Via The Motley Fool

Topics Intellectual Property

2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down

April 24, 2026

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...

Via StockStory

Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

April 22, 2026

From Gilead Sciences, Inc.

Via Business Wire

What's Going On With Arcus Biosciences Stock On Wednesday? ↗

April 22, 2026

Arcus Biosciences halts STAR-121 lung cancer trial after futility review while Gilead Science declines option extension.

Via Benzinga

Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others ↗

April 20, 2026

Eli Lilly said Monday it will spend up to $7 billion to buy privately held Kelonia Therapeutics for its suite of cancer drugs.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Multimedia
Local Events
Classifieds
Obituaries
Weather
Online Features

Services

About Us
Contact Us
Promote Your Event
Subscriber Services
Online Forms
Rack Locations

woonsocketcall.com
Address: 154 Main Street
Woonsocket, RI 02895
Phone: 401-762-3000
Email: notices@woonsocketcall.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Gilead Sciences (NQ:GILD)

All News about Gilead Sciences

Sections

Services